AI brief of an SEC Form 8-K · ABVC BIOPHARMA, INC. (ABVC)

ABVC BioPharma completes distribution of 15% of BioKey Cayman shares to stockholders

Neutral Impact 3 of 5 restructuring Written later

ABVC BioPharma completed the separation of its subsidiary BioKey Cayman, distributing about 15% of BioKey Cayman's ordinary shares to ABVC common stockholders as a pro rata dividend effective August 21, 2026. ABVC retains about 85% ownership and control, and BioKey Cayman is no longer a wholly owned subsidiary, but no trading market for its shares exists yet and it intends to seek OTC Markets quotation.

Key points

Distribution of 4,500,390 BioKey Cayman ordinary shares, at 0.169464 share per ABVC common share held at the close of business on July 24, 2026
Distribution effective 11:59 p.m. New York City time on August 21, 2026; ABVC holds approximately 85% of BioKey Cayman
No trading market exists yet; BioKey Cayman plans to seek OTC Markets quotation and has no trading symbol

The filing

CompanyABVC BIOPHARMA, INC. (ABVC)

Form8-K, current report

Filed with the SECAug 27, 2026, 8:30 AM ET

Accession number0001213900-26-094152

Items reported: 1.01 Material Definitive Agreement 2.01 Acquisition or Disposition Completed 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.